 The FDA has cleared Adagene Incs NASDAQ: ADAG Phase 1b2 clinical trial of its anti-CTLA-4 monoclonal antibody mAb, ADG126, in combination with Merck Co Incs NYSE: MRK Keytruda pembrolizumab. The global trial ADG126-P001 KEYNOTE-C98 will. 